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The factors involved in thymus regeneration after chemotherapy has not been sufficiently 
explored. This study was aimed to identify the clinical characteristics and single-nucleotide 
polymorphisms in the gene (IL7R) encoding IL-7Rα associated with thymus renewal 
after chemotherapy in Chinese Han individuals with lymphoma. The dynamics of thymic 
activity in 134 adults with Hodgkin lymphoma (HL) and B cell lymphoma from baseline to 
12 months post-chemotherapy were analyzed by assessing thymic structural changes 
using serial computed tomography scans and correlating these with measurements of 
thymic output by concurrent analysis of single-joint T-cell receptor excision circles (sjTREC) 
and CD31+ recent thymic emigrants (RTE) in peripheral blood. The association of clinical 
variables and IL7R polymorphisms with the occurrence of rebound thymic hyperplasia 
(TH) and the recovery of thymic output following chemotherapy were evaluated. Thymic 
regeneration was observed, with the evidence that TH occurred in 38/134 (28.4%) cases, 
and thymic output, assessed by CD31+ RTE numbers and sjTREC content, recovered 
to baseline levels within 1 year after the end of therapy. The frequencies of the T allele 
and TT + GT genotype of rs7718919 located in the promoter of IL7R were significantly 
higher in patients with TH compared with those without TH (P =  0.031 and 0.027, 
respectively). In contrast, no significant difference was found between two groups with 
respect to the distribution of allele and genotype frequencies of rs6897932. By general 
linear models repeated-measure analysis, rs7718919 and rs6897932 were determined 
to exert no significant effects on the recovery of thymic output after therapy. Univariate 
analysis revealed host age under 30, the diagnosis of HL, baseline thymic index and 
CD31+ RTE counts, and rs7718919 genotype as potential predictors for TH after 
chemotherapy (P < 0.05); after multivariate adjustment, only host age was independently 
associated with the occurrence of TH (odds ratios = 4.710, 95% confidence intervals: 
1.727–12.845, P = 0.002). These findings indicate that patient age is an independent 
predictor for thymic regrowth after chemotherapy, which should promote awareness 
among physicians to make a timely diagnosis of TH in young adults and help physicians 
to prioritize intervention strategies for thymus rejuvenation in this population.
Keywords: thymus, hyperplasia, regeneration, lymphoma, chemotherapy, interleukin-7 receptor-α, single-
nucleotide polymorphisms
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inTrODUcTiOn
Atrophy of the thymus caused by cytotoxic drugs and glucocorti-
coid hormones remains a primary obstacle to full immune recov-
ery following chemotherapy, which is dependent on high thymic 
output of new recent thymic emigrants (RTE) to replenish the 
naïve T cell pool (1, 2). Failure of restoration of thymus function 
may lead to increased risks of infections and tumor recurrence, 
particularly in elderly patients where the thymus is atrophied 
(1, 3). Enlargement of the thymus above baseline following 
chemotherapy, known as rebound thymic hyperplasia (TH), 
sometimes occurs during recovery from chemotherapy (4). TH 
may be related with robust thymic regeneration and is character-
ized by an increase in thymic size and density, concurrent with the 
restoration of thymic output of T cells (5–7). This phenomenon 
is common in children and adolescents and can occasionally be 
observed in young adults; however, it is rare in older patients (4, 
8–11). Therefore, more effort should be made toward restoring 
thymic function in post-pubertal patients. However, the factors 
involved in thymus atrophy and regeneration are not fully under-
stood, and approaches to stimulate rejuvenation of the thymus 
remain limited (12).
Clinical factors associated with thymic regrowth after chemo-
therapy have been explored in previous studies. Information on 
the occurrence of TH following chemotherapy obtained from 
different age groups revealed that the renewal ability of the thy-
mus may be influenced by host age, and TH after chemotherapy 
is more common in younger populations with greater amounts 
of residual thymic tissues and higher thymic activity (4–11). 
Whereas, thymic regrowth is not likely associated with the tumor 
types and treatment. It can occur following treatment for various 
malignancies, of which malignant lymphoma is the most com-
mon (8). Besides, TH after cessation of chemotherapy does not 
appear to be influenced by the degree of lymphocyte depletion, 
but appears to be a common response to the withdrawal of chemo-
therapy (4, 6). There is also evidence that TH after chemotherapy 
maybe associated with endocrine dysfunctions (13). However, 
the factors mentioned above need to be further validated, since 
the knowledge of TH after chemotherapy was mainly obtained 
from analysis of small patient groups, and other potential factors 
related with TH have not been elicited.
Interleukin-7 (IL-7) acts as a non-redundant cytokine in 
thymic development (14). Under conditions of lymphopenia, 
it could optimize the long-term recovery of T cell diversity 
by restoring thymic function (15, 16). In patients with human 
immunodeficiency virus (HIV) infection, those with higher 
baseline levels of IL-7 had a higher incidence of TH after 
therapy (17). Patients with rheumatoid arthritis and type 
1 diabetes demonstrating positive responses to treatment 
exhibited raised plasma IL-7 levels concurrent with renewed 
thymopoeisis (18, 19). Thus, IL-7 may be an important factor 
in thymic regeneration after injury. The responsiveness of IL-7 
is dependent on the expression of the IL-7 receptor (IL-7R), 
which is a heterodimer consisting of the common γ-chain 
and the α-chain (IL-7Rα) (20, 21). The gene encoding IL-7Rα 
(IL7R) is polymorphic, and single-nucleotide polymorphisms 
(SNPs) in IL7R could potentially affect its transcription, thereby 
influencing IL-7Rα expression levels and signal transduction 
(22–26). IL7R polymorphisms are likely to modulate the regula-
tion, differentiation, and function of T cell subsets and are 
associated with the susceptibility to autoimmune diseases, the 
pathogenesis of graft-versus-host disease after hematopoietic 
stem cell transplantation (HSCT), and T cell repopulation 
after lymphocytopenia caused by HIV infection and HSCT 
(22–32). Moreover, SNPs in IL7R may influence thymic T cell 
development in patients with multiple sclerosis (MS) (25), 
indicating a possible role for these SNPs in the process of 
thymic regeneration after chemotherapy.
Considering these elements, the present study was aimed at 
examining clinical predictors for the occurrence of TH in a group 
of adult patients undergoing chemotherapy for lymphoma and 
exploring the possible contribution of IL7R polymorphisms to 
thymic renewal capacity by detecting possible links between IL7R 
SNPs and the recovery of thymic volume and output function 
after chemotherapy.
MaTerials anD MeThODs
Patients
Chinese Han patients with Hodgkin lymphoma (HL) and B cell 
lymphoma (n = 193) admitted to the Department of Hematology, 
the First Affiliated Hospital of Nanjing Medical University 
between January 2012 and June 2015 were included in this study. 
All subjects provided written informed consent in accordance 
with the requirements of the Declaration of Helsinki. The study 
was approved by the Ethics Committee of the First Affiliated 
Hospital of Nanjing Medical University. All patients accepted 
chemotherapy for lymphoma at diagnosis. For patients with HL, 
ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine) 
regimen was administered. Patients with diffuse large B cell 
lymphoma (DLBCL) were treated with R-CHOP (rituximab, 
cyclophosphamide, doxorubicin, vincristine, and prednisone) 
or R-DA-EPOCH (rituximab, etoposide, prednisone, vincristine, 
cyclophosphamide, and doxorubicin) regimen. Patients with 
follicular lymphoma (FL) or marginal zone lymphoma (MZL) 
accepted R-CHOP regimen mentioned above or R-COP (rituxi-
mab, cyclophosphamide, vincristine, and prednisone) regimen. 
Patients with Burkitt lymphoma (BL) received R-hyperCVAD 
(rituximab, cyclophosphamide, vincristine, doxorubicin, and 
dexamethasone) therapy alternating with R-MA (rituximab, 
methotrexate, and cytarabine). CT examinations were performed 
before (baseline), during (after three cycles of chemotherapy), and 
after (0, 3, 6, 9, and 12 months post-chemotherapy) treatment. 
Simultaneously, blood samples were collected for flow cytometric 
analyses and peripheral blood mononuclear cells (PBMCs) sepa-
rated by density gradient centrifugation. Patients (n = 28) who 
had no response to therapy, or had disease progression within 
1 year after the end of treatment, were excluded. Patients (n = 15) 
who responded to chemotherapy and underwent HSCT as first-
line consolidation were also excluded. For 16 patients, it was not 
possible to determine thymus size because of the growth of the 
lymphoma. The remaining 134 patients (82 DLBCL, 15 HL, 14 
FL, 10 MZL, 4 BL, and 9 others), aged 18−67 (median 41) years, 
were included.
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Thymus imaging
Serial analyses of structural changes of the thymus were per-
formed by reviewing CT images. Thymic size was scored using 
a thymic index on a scale from 0 to 5 as described elsewhere 
(6): 0, no soft tissue; 1, minimal soft tissue, barely recognizable; 
2, minimal soft tissue, more obvious; 3, moderate soft tissue; 
4, moderate soft tissue of greater extent, almost mass-like; and 
5, mass-like appearance, suggesting hyperplasia or thymoma. 
Thymic enlargement, or subsequent regression, was defined as a 
change in score of at least 1 on this 0–5 scale. Enlargement of the 
thymus over baseline in the absence of any clinical, laboratory, or 
radiological signs of disease progression was interpreted as TH.
cD31+ rTe Detection
For immunophenotypic analysis, whole blood samples were 
stained by four-color technique using anti-CD45RA-FITC, 
anti-CD31-PE, anti-CD4-PerCP, and anti-CD3-APC mono-
clonal antibodies and appropriate isotope controls (Becton 
Dickinson, USA). Erythrocytes were lysed with lysis solution 
(Becton Dickinson, USA). Lymphocyte data were analyzed 
by flow cytometry using a FACSCalibur (Becton Dickinson, 
USA). After gating for CD3+ and CD4+ cells, the percentage of 
CD31+ cells among all CD45RA+CD4+ T cells was analyzed with 
CELLQuestTM software (Becton Dickinson, USA) as previously 
described (33). Whole blood lymphocyte counts were performed 
with an automated analyzer, and the absolute numbers of CD31+ 
RTEs were determined by multiplying the total lymphocyte count 
by the percentage of CD31+CD45RA+CD4+ T cells.
IL7R genotyping
Genomic DNA samples were extracted from PBMCs using a 
QIAamp DNA Blood Midi Kit (Qiagen, Germany), according to 
the manufacturer’s instructions. On the basis of a literature search, 
four SNPs were chosen as our primary targets of investigation, 
including rs6897932 in exon 6, and rs7718919, rs11567685, and 
rs11567686 in the promoter region, of IL7R (22–25). Genotyping 
was performed by DNA sequencing. Briefly, the amplicons 
containing the promoter and exon 6 regions of IL7R were PCR-
amplified from genomic DNA samples using primer sequences 
previously reported (22). PCR products were then purified by 
polyethylene glycol precipitation. Next, DNA sequencing was 
performed in both directions using the ABI Prism Big Dye 
Terminator version 3.1 sequencing kit and an ABI 3730XL Genetic 
Analyzer. Sequencing results were analyzed using Chromas 2.22 
software (Technelysium, Australia).
single-Joint T-cell receptor excision 
circles (sjTrec) analysis
Serial quantification of sjTREC in the DNA of PBMCs was 
performed using a TaqMan real-time quantitative PCR assay 
and a StepOnePlus instrument (Applied Biosystems, USA), as 
previously described (5). A standard curve based on a plasmid 
preparation containing the sjTREC target sequence was plotted, 
and sjTREC values for samples were calculated using StepOne 
software (Applied Biosystems, USA). Samples were analyzed in 
triplicate, and median values calculated. Data are expressed as 
TRECs/106 cells.
statistics
Continuous variables are expressed as means ±  SD and cat-
egorical variables as number of cases (percentage). Independent 
t tests or Mann–Whitney U tests were used to evaluate differences 
in numerical data. Chi-square or Fisher’s exact tests were used 
to assess differences in categorical data and to compare geno-
type and allele frequencies between patients with and without 
TH. Odds ratios (OR) and 95% confidence intervals (CI) were 
calculated for the assessment of risk factors. Genotyping data 
were analyzed for Hardy–Weinberg equilibrium (HWE) and 
linkage disequilibrium (LD) using HaploView 4.2. LD blocks 
were identified using the CI setting. Univariate and multivariate 
logistic regression models were performed to investigate the 
associated factors for TH after chemotherapy. Variables with 
P value < 0.10 in the univariate analysis were selected for the 
multivariate analysis. The changes of thymic output at different 
time points were assessed by general linear models repeated-
measure analysis using the statistical test within-subject con-
trasts. The effect of IL7R SNPs on thymic output recovery was 
evaluated by general linear models repeated-measure analysis 
using between-subject contrasts. Data analysis was performed 
using SPSS21 statistical software. Values of P < 0.05 were con-
sidered to be significant.
resUlTs
The Occurrence of Th after chemotherapy
Thymic hyperplasia was observed in 38/134 (28.4%) patients 
within intervals ranging from 1 to 10 months (median, 4 months) 
after the cessation of chemotherapy. Compared with those with-
out TH (n = 96), patients with TH (n = 38) after chemotherapy 
were much younger, with larger thymic volumes, and higher 
thymic output before treatment (P <  0.05). Moreover, patients 
with TH were more commonly diagnosed with HL treated with 
chemotherapy only (P < 0.05). However, no significant differences 
were observed in sex, disease stage, and the pool size of peripheral 
CD4+ T-cells at baseline between two groups (P > 0.05). The clini-
cal characteristics of these patients are presented in Table 1.
recovery of Thymic Output after 
chemotherapy
The change in thymic output during and after chemotherapy was 
analyzed in 84 patients with available CD31+ RTE and sjTREC 
data at all follow-up time points (Figure 1). Consistent with our 
previous findings (5), both the numbers of CD31+ RTE and levels 
of sjTREC approached a nadir at the end of treatment (P < 0.001). 
During follow-up, CD31+ RTE counts and sjTREC levels rose 
significantly and reached pretreatment levels at 9 and 6 months 
after the end of chemotherapy, respectively (P = 0.035 and 0.001, 
respectively).
The effect of IL7R Polymorphisms  
on Th after chemotherapy
Genotypes for rs11567686 did not conform to HWE (P = 0.029) 
and were excluded from further analyses. Genotypes of the 
three remaining SNPs were all consistent with HWE (P > 0.05); 
FigUre 1 | The recovery of thymic output measured by cD31+ recent thymic emigrants (rTe) (a) and single-joint T-cell receptor excision circles 
(sjTrec) (B) in peripheral blood within 1 year after the end of chemotherapy in 84 patients. Both the CD31+ RTE counts and sjTREC levels decreased to 
the nadir at the end of treatment and recovered within 1 year of follow-up. Data are shown as means ± SD. P values were assessed by general linear model analysis 
for repeated-measure data. *P < 0.001 vs. baseline levels; #P < 0.05 vs. the nadir at the end of treatment.
TaBle 1 | Baseline characteristics of patients with and without thymic hyperplasia (Th) after chemotherapy.
characteristics Patients with Th (n = 38) Patients without Th (n = 96) P-value
Age (years), median (IOR) 30 (18–53) 48 (18–67) <0.001
Gender, n (%)
 Female 20/38 (53) 59/96 (61) 0.436
 Male 18/38 (47) 37/96 (39)
Disease type, n (%)
 DLBCL 18/38 (47) 64/96 (67) 0.038
 HL 8/38 (21) 7/96 (8)
 Others 12/38 (32) 25/96 (26)
Disease stage, n (%)
 I–II 18/38 (47) 33/96 (34) 0.163
 III–IV 20/38 (53) 63/96 (66)
Treatment, n (%)
 Chemotherapy 8/38 (21) 7/96 (8) 0.023
 Chemotherapy + rituximab 30/38 (79) 89/96 (92)
CD4+ T cells counts (×109/L) 642.27 ± 385.79 577.67 ± 365.14 0.756
Thymic index, n (%)
 0 3/38 (8) 45/96 (47) <0.001
 1 10/38 (26) 23/96 (24)
 2 19/38 (50) 21/96 (22)
 3 5/38 (13) 6/96 (6)
 4 1/38 (3) 1/96 (1)
Thymic output
 CD31+RTE (×109/L) 194.85 ± 158.31 98.12 ± 84.87 0.036
 sjTREC (copies/106 PBMCs) 10,381.09 ± 8,393.22 5,109.70 ± 7,162.70 0.042
DLBCL, diffuse large B cell lymphoma; HL, Hodgkin lymphoma; RTE, recent T cell emigrant; sjTREC, single-joint T-cell receptor rearrangement excision circle; PBMCs, peripheral 
blood mononuclear cells.
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however, the minor allele frequency of rs11567685 (0.019%) was 
too low for differences between the two groups to be meaning-
fully analyzed. Therefore, allele and genotype frequencies for 
rs7718919 and rs6897932 in patients with and without TH were 
compared (Table 2).
The minor T allele of rs7718919 was significantly more frequent 
in patients with TH compared with those without TH (P = 0.031, 
OR = 2.171, 95% CI 1.064–4.433, T vs. G). We also detected a 
significant difference under a recessive model with regard to 
the distribution of rs7718919 genotype frequencies between 
patients with and without TH (P = 0.027, OR = 2.528, 95% CI 
1.097–5.826, TT + GT vs. GG); however, no significant evidence 
was detected under a dominant model (P = 0.622, OR = 1.722, 
95% CI 0.276–10.737, TT vs. GG + GT). Moreover, no significant 
difference was found with respect to the distribution of allele and 
genotype frequencies of rs6897932 between subjects with and 
without TH (P = 0.383 and 0.282, respectively).
Due to high diversity and weak LD (r2  =  0.365) between 
rs7718919 and rs6897932, haplotype analyses were not possible 
in our study cohort.
TaBle 2 | genotype distribution and allele carriage rates of two single-nucleotide polymorphisms (snPs) in the gene encoding il-7rα in patients with 
and without thymic hyperplasia (Th) following chemotherapy.
snP locus genotype/allele Patients with  
Th (n = 38)
Patients without  
Th (n = 96)
Odds ratios  
[95% confidence intervals]
P-value
rs7718919 GG
GT
TT
24 (0.632)
12 (0.316)
2 (0.053)
78 (0.812)
15 (0.156)
3 (0.031)
0.084
TT
GG + GT
2 (0.053)
36 (0.947)
3 (0.031)
93 (0.969)
1.722 [0.276–10.737] 0.622
GT + TT
GG
14 (0.368)
24 (0.632)
18 (0.187)
78 (0.813)
2.528 [1.097–5.826] 0.027
T
G
16 (0.211)
60 (0.789)
21 (0.109)
171 (0.891)
2.171 [1.064–4.433] 0.031
rs6897932 CC
CT
TT
27 (0.711)
11 (0.289)
0 (0.000)
59 (0.615)
34 (0.354)
3 (0.031)
0.383
CC + CT
TT
38 (1.000)
0 (0.000)
93 (0.969)
3 (0.031)
1.413 [1.265–1.578] 0.577
CC
CT + TT
27 (0.711)
11 (0.289)
59 (0.615)
37 (0.385)
1.539 [0.683–3.469] 0.325
C
T
65 (0.855)
11 (0.145)
152 (0.792)
40 (0.208)
1.555 [0.751–3.220] 0.282
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The effect of IL7R Polymorphisms on the 
recovery of Thymic Output after 
chemotherapy
As previously shown in Ref. (4), thymic regeneration after chemo-
therapy manifests as an increase in thymic volume, concurrent 
with the restoration of thymopoiesis. We investigated the influ-
ence of rs7718919 and rs6897932 on the renewal of thymopoiesis 
following chemotherapy in 84 patients with thymic output data 
available for all follow-up time points.
The effect of rs7718919 genotypes was tested using a recessive 
model (TT + GT vs. GG), due to few cases carrying the minor 
allele T. By general linear models repeated-measure analysis, no 
impact of rs7718919 genotypes was found on the recovery of 
CD31+ RTEs counts and sjTREC levels within 1 year of follow-up 
(P = 0.743 and 0.642, respectively) (Figure S1 in Supplementary 
Material). Similarly, the effect of rs6897932 genotype was tested 
using a recessive model (CC vs. CT + TT) and no impact was 
found on the restoration of thymic output measured by both 
CD31+ RTEs counts and sjTREC levels (P =  0.913 and 0.896, 
respectively) (Figure S2 in Supplementary Material). Baseline 
characteristics, including age, sex, disease type and stage, CD4+ 
cell counts, and output function at baseline were comparable 
between the two groups with different genotypes (P  >  0.05) 
(Table S1 in Supplementary Material).
analysis of Factors associated with 
Th after chemotherapy
The univariate analysis results showed significant differences 
between patients with and without TH in terms of host age, dis-
ease type, pretreatment thymic size and CD31+ RTE counts, and 
rs7718919 genotype (P < 0.05) (Table 3). Then, by multivariate 
analysis, it was concluded that host age under 30 is the only 
independent predictive factor for the occurrence of TH after 
chemotherapy (P = 0.002, OR = 4.710, 95% CI: 1.727–12.845). A 
higher probability of thymic regrowth following chemotherapy 
was observed in subjects with the T allele of rs7718919; how-
ever, this trend did not reach statistical significance (P = 0.093, 
OR = 2.308, 95%CI: 0.875–6.091) (Table 3).
DiscUssiOn
Reactive TH after chemotherapy is a well-documented phenom-
enon in children, adolescents, and young adults, but is rare in 
older patients, suggesting a high thymic regenerative capacity in 
the young (4, 5, 8–11). However, by monitoring thymic output, 
it was determined that substantial output is maintained into late 
adulthood despite the decline of thymic function with age, and 
even the aged thymus retains the ability to renew thymopoiesis 
(34). This study further explored the influence of age on the 
renewal capacity of the thymus following chemotherapy. In the 
cohort of adults accepting chemotherapy for lymphoma, TH 
was observed in 38 (28.4%) cases aged 18–53  years (median 
30), who were much younger, with larger thymic volumes and 
higher thymic output before treatment than those without TH, 
suggesting a high renewal capacity was retained in the thymus 
of young adults. In contrast, TH was observed in none of the 
elderly, possibly due to a decreased regenerative capacity of the 
thymus with age, which could represent a decline in the intrin-
sic capacity of lymphopoietic stem cells and/or changes in the 
thymic microenvironment (7). Besides, by multivariate analysis, 
patient age under 30 was revealed as an independent predictor 
for the occurrence of TH, further supporting the conclusion that 
thymic renewal capacity after chemotherapy is age-dependent. 
TaBle 3 | The univariate and multivariate analysis of factors influencing the occurrence of thymic hyperplasia after chemotherapy.
Parameters Univariate analysis 
Odds ratios (Or)  
[95% confidence intervals (ci)] P-value
Multivariate analysis 
Or [95% ci] P-value
Age ≤30 years 8.054 [3.415–18.991] <0.001 4.710 [1.727–12.845] 0.002
Gender: female 1.435 [0.673–3.062] 0.350
Disease type: HL 3.390 [1.134–10.140] 0.029 2.279 [0.646–8.036] 0.200
Disease stage: I−II 1.718 [0.801–3.687] 0.165
Baseline thymic index ≥2 4.670 [2.059–10.412] <0.001 2.087 [0.774–5.628] 0.146
Baseline CD4+ T cell counts ≥600 × 109/L 1.950 [0.445–8.548] 0.376
Baseline CD31+ RTE counts ≥150 × 109/L 3.896 [1.059–14.326] 0.041 2.160 [0.430–10.845] 0.350
Baseline sjTREC levels ≥7,000 copies/106 PBMCs 4.050 [0.974–16.842] 0.054 3.052 [0.277–18.040] 0.362
Rs7718919 genotype: TT + GT 2.528 [1.097–5.826] 0.029 2.308 [0.875–6.091] 0.093
HL, Hodgkin lymphoma; RTE, recent T cell emigrant; sjTREC, single-joint T-cell receptor rearrangement excision circle; PBMCs, peripheral blood mononuclear cells.
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Consistent with this, we have revealed in an earlier study that, 
the majority (70%) of TH following chemotherapy was found 
in individuals under 30  years, although it can occasionally 
be observed in middle-aged patients (10). Furthermore, the 
renewal of thymopoiesis following chemotherapy was evalu-
ated in the present study. The fast restoration of thymic output 
within 1 year of follow-up observed in these adults suggested 
a renewed thymopoiesis. Thymus regeneration, manifesting as 
partial reversal of thymic atrophy concurrent with a renewed 
thymopoiesis, in young adults undergoing chemotherapy 
would contribute to immune recovery, enhancing the clinical 
relevance of developing strategies to booster thymic activity in 
this population (2, 5, 12).
Clinical features except for patient age associated with 
thymic regrowth after chemotherapy have not been studied 
in-depth. Based on previous observations, it was seemed that, 
TH is neither tumor nor treatment specific (4, 6, 8). This study 
revealed that, patients with TH after chemotherapy were more 
commonly diagnosed with HL than those without TH. While, 
by multivariate analysis, the diagnosis of HL was not associated 
with the occurrence of TH independently, it can be conceived 
that, the lower age of patients with HL may contribute to a higher 
probability of thymic regrowth. Whether thymic regrowth fol-
lowing chemotherapy is correlated with the biological proper-
ties of the tumors remains unknown. It should be reminded 
that, the influence of rituximab usage on the occurrence of 
TH post-chemotherapy cannot be excluded, since HL patients 
were treated with chemotherapy only, in contrast with patients 
with B cell lymphoma accepted chemotherapy combined with 
rituximab. Emerging data suggest that rituximab has an inhibi-
tory effect on effector T cells and could induce regulatory T cells 
expansion, which may be related to B cell deprivation resulting 
in impaired antigen-presenting cells activity and reduced pro-
duction of co-stimulatory and immuno-modulatory molecules 
taking part in T cell activation and interactions; besides, it 
could exert a direct effect on T cells by binding to a specific 
T cell subset expressing CD20 (35). A recent study confirmed 
that, CD20 was also expressed on mature medullary thymocytes 
(36). Therefore, rituximab may intervene T cell development in 
the thymus by targeting CD20+ thymocytes. Unfortunately, this 
study design precluded an analysis for the effect of rituximab. 
Whether the use of rituximab could affect thymic activity and 
thus delay the regeneration of the thymus in patients with B 
cell lymphoma deserves further studies. Moreover, TH was 
demonstrated to be caused by chemotherapy-induced gonadal 
atrophy, which results in increased luteinizing hormone secre-
tion (13), and sex steroid ablation has been regarded as an 
important candidate strategy for the improvement of thymic 
regeneration (12). Thus, the sex-related endocrine status is 
presumed to influence the renewal capacity of the thymus after 
chemotherapy. However, sex ratio was comparable in cases 
with and without TH in this study, excluding sex as a predic-
tor for TH. Measurement of sex-related endocrine function 
is warranted to clarify this issue. In addition, the occurrence 
of TH in this cohort of adults we studied was not influenced 
by the size of peripheral CD4+ T cell pool as expected, since 
renewed thymopoiesis correlated with TH play a limited role 
in the early repopulation of peripheral CD4+ T cells following 
chemotherapy in adults (10).
The mechanisms for the reconstitution of thymic cellularity, 
accompanied by the restoration of thymic T cell development, 
after the removal of chemo-therapeutic toxicity is complex 
(37, 38). Interleukin-7, a growth and anti-apoptotic factor for 
T cells, was found to be associated with thymus enlargement in 
HIV patients undergoing antiretroviral therapy, suggesting an 
important role of IL-7 in thymus regrowth (17). Consistent with 
this findings, administration of recombinant human IL-7 was 
shown to increase the numbers of RTEs and levels of TRECs and 
results in a broadening of the T-cell receptor repertoire, indicat-
ing increased thymopoiesis (39). The response of thymocytes to 
IL-7 correlates with IL-7Rα expression. Accordingly, this study 
focused on four specific SNPs within the IL7R locus, known to 
influence the IL-7Rα expression on T cells (23–25), and explored 
their potential contributions to the thymic regeneration after 
chemotherapy in adults with lymphoma. It was found that the 
frequencies of the minor allele T and the TT + GT genotype of 
rs7718919, located in the promoter region of IL7R, were higher 
in patients with TH compared with those without TH. These 
results provided a possible link between rs7718919 and thymus 
enlargement after chemotherapy. Considering rs7718919 could 
potentially influence the expression of IL-7Rα as a transcrip-
tion factor binding site (30), it is conceivable that it may affect 
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IL-7-mediated regulation of thymocytes, and thus be implicated 
in thymic regrowth. However, this association between rs7718919 
and the occurrence of TH was not confirmed by multivariate 
analysis. Moreover, we did not observe an accelerated recovery 
of thymic output after chemotherapy in patients with TT + GT 
genotype compared with GG genotype carriers, suggesting that 
the presence of the rs7718919 T allele had limited effects on 
the restoration of thymopoiesis. Consistent with these results, 
Shamim et  al. (31) were unable to demonstrate any associa-
tion between IL7R polymorphisms and TREC levels before or 
after HSCT in a Danish cohort. Nevertheless, the influence 
of rs7718919 polymorphisms on the renewal of thymopoiesis 
should be carefully evaluated. As IL-7Rα expression is finely 
tuned and differentially regulated during thymocyte develop-
ment (21), it is important to better understand which thymocyte 
subset could be influenced by the altered IL-7 signaling associ-
ated with rs7718919 and to what extent this could affect thymic 
T cell development.
This study also investigated rs6897932, a missense polymor-
phism located in exon 6 of IL7R, which encodes the trans-mem-
brane region of IL-7Rα. The C allele of rs6897932 is associated 
with increased skipping of exon 6, resulting in a higher ratio 
of membrane-bound vs. soluble receptor, which could cause 
reduced IL-7Rα expression on T cells (26). In a Danish cohort, 
homozygosity for the rs6897932 T-allele was associated with 
more rapid CD4+ T-cell recovery after the initiation of antiret-
roviral therapy (28). Unfortunately, the design of that study did 
not allow evaluation of whether the increase in CD4+ T cells was 
caused by increased thymopoiesis or expansion of the periph-
eral T-cell pool. Our study revealed no significant association 
of rs6897932 polymorphisms with either thymic enlargement 
or the restoration of thymic output, indicating a limited role 
for rs6897932 variants in thymopoiesis recovery after chemo-
therapy. This is consistent with the report by Broux et al. (25) 
of no influence of rs6897932 polymorphisms on thymopoiesis, 
as measured by the frequency of CD31+ RTEs in MS patients 
and healthy controls. Further studies investigating the potential 
effects of rs6897932 on the expression of IL-7Rα and its possible 
influence on the affinity and/or signaling of IL-7Rα in various 
thymocyte subsets are warranted to elucidate its role on thymo-
poietic activity. In addition, rs11567685, located in the promoter 
region of IL7R, was included in this study. It could potentially 
influence thymic development and peripheral homeostasis of 
T cells by altering the expression of IL-7Rα on CD4+ T cells in 
MS patients (25). Unfortunately, the effect of rs11567685 on the 
recovery of thymic cellularity and function after chemotherapy 
in this study cannot be evaluated, due to its low minor allele 
frequency.
This study has some limitations. Our observations were based 
on relatively few cases, and this may have masked significant 
effects due to lack of statistical power. In addition, thymic output 
measured by determination of sjTREC and CD31+ RTE may be 
influenced by the proliferation of peripheral T cells, potentially 
leading to an underestimation of thymic activity (40, 41). Hence, 
future studies with larger sample sizes and more accurate tools 
for thymic output measurement are necessary to further define 
the factors associated with thymic regrowth after chemotherapy. 
Moreover, evaluating the effect of rituximab usage on thymus 
regeneration following chemotherapy by comparing the occur-
rence of TH and the recovery of thymic output in two groups with 
comparable clinical features, including age, sex, disease type and 
stage, thymic size, and output function at baseline, is warranted 
in future studies.
To conclude, these findings suggest that patient age is an 
independent predictor for thymic regrowth after chemotherapy, 
which should promote awareness among physicians to make a 
timely diagnosis of TH in young adults and help physicians to 
prioritize intervention strategies for thymus rejuvenation after 
chemotherapy in this population. Besides, the potential link 
between the IL7R SNP and thymic regrowth after chemotherapy 
warrant further investigations, given the key roles of IL-7 and 
IL-7Rα in thymic development. These results will contribute to an 
improved understanding of the mechanisms involved in thymic 
regeneration.
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